InsiderClue
Insiders · Profile

Frankenfield Christopher James

Chief Financial Officer at Xilio Therapeutics. Filing since 2 Jan 2025. CIK 0001988344

Company
Date
Role
Action
Shares
Amount
Of holding
XLO Xilio Therapeutics, Inc.
2 Jan 2026
Chief Financial Officer
Sold on a plan
7,030
$4.52K
22.1%
XLO Xilio Therapeutics, Inc.
2 Jan 2025
Chief Financial Officer
Sold on a plan
6,954
$6.84K
35.9%
2 decisions on file.